Prothrombin complex concentrate

Why this drug is interesting

Prothrombin complex concentrate is the reason a patient with an intracranial haemorrhage on warfarin can have a normal INR twenty minutes after arriving, rather than four hours and two litres of plasma later. It contains the four vitamin K-dependent procoagulant factors — II, VII, IX and X — in a 40 mL volume, at concentrations plasma cannot approach.

The conceptual trap is in the dosing. PCC is dosed off the pre-treatment INR, and the INR corrects almost immediately — but the factors it supplies have half-lives measured in hours, and factor VII's is 1.5 to 6 hours. The patient's own liver is still not making any of them, because the warfarin is still there. A normal INR at thirty minutes tells you the concentrate arrived; it tells you nothing about where the patient will be at midnight.

What is in the vial

Three things follow from that table. Factor IX is the only factor with a fixed value, which is why the product is labelled and dosed in units of factor IX — every other component is a range. The concentrate includes the natural anticoagulants protein C and protein S, which is a deliberate design feature intended to reduce the thrombotic risk that earlier concentrates carried. And it contains heparin, which is not incidental — see the contraindications.

It is a plasma-derived product. Despite viral inactivation steps, the label states that transmission of infectious agents cannot be entirely excluded, and names parvovirus B19 specifically.

Indications and dosing

Licensed indications

• Bleeding and perioperative prophylaxis in acquired deficiency of the prothrombin complex factors — "such as deficiency caused by treatment with vitamin K antagonists, or in case of overdose of vitamin K antagonists, when rapid correction of the deficiency is required" — the final clause is a real limit on the licence, and §4.4 repeats it
• Bleeding and perioperative prophylaxis in congenital deficiency of factors II and X when a specific factor product is unavailable

Note what is not there: no indication for direct oral anticoagulant reversal, and no indication for trauma coagulopathy or liver disease. Both uses occur; both are off-label.

Vitamin K antagonist reversal

Administration

• Reconstitute and give intravenously at 0.12 mL/kg/min (~3 units/kg/min), up to a maximum of 8 mL/min (~210 units/min)
• Aseptic technique; do not mix with other medicinal products
• Monitoring of INR during treatment is mandatory — the label describes its own dose recommendations as empirical, with variable recovery and duration
• No data are available on use in children

Congenital factor II or X deficiency

Where a specific factor concentrate is unavailable, dosing is calculated from the desired factor rise:

• Factor X: required units = weight (kg) × desired factor X rise (IU/mL) × 60
• Factor II: required units = weight (kg) × desired factor II rise (IU/mL) × 50

Contraindications and hazards

Contraindications

• Hypersensitivity to the active substances or excipients
• Known allergy to heparin, or a history of heparin-induced thrombocytopenia — the product contains 200–500 IU of heparin per 1000 IU vial
• IgA deficiency with documented anti-IgA antibodies

Thrombosis and DIC

The central risk of any prothrombin complex concentrate is that it does exactly what it is designed to do, in the wrong place. The label warns of "risk of thrombosis or disseminated intravascular coagulation… particularly with repeated dosing," and directs close monitoring in coronary disease, liver disease, the perioperative period, neonates, and patients otherwise at high thrombotic risk.

Reported adverse reactions include deep vein thrombosis (common); thrombosis, pulmonary embolism, hypertension, bronchospasm, haemoptysis, epistaxis, anxiety, raised D-dimer, abnormal liver function and injection-site burning (uncommon); and, post-marketing, anaphylactic shock, cardiac arrest, circulatory collapse, respiratory failure and urticaria.

Off-label uses

Direct oral anticoagulant-associated bleeding

PCC is widely used for major bleeding on a factor Xa inhibitor where a specific reversal agent is unavailable, unfunded or not indicated — which, given that NICE recommends andexanet alfa only for gastrointestinal bleeding, is most UK situations. It is off-label, the evidence is observational, and the mechanism is different: PCC does not remove the anticoagulant, it overwhelms it by supplying substrate downstream. Typical reported doses are higher than for warfarin reversal, and this is a decision to take with haematology and your local network protocol, not from a monograph.

PCC has no useful role in dabigatran reversal, for which idarucizumab is the specific agent.

Trauma and liver disease

Both are off-label. In major trauma the UK approach is a haemostatic resuscitation protocol with blood components and tranexamic acid; PCC has a role in some algorithms, particularly for the anticoagulated trauma patient, but is not a substitute for the protocol. In liver disease the INR is a poor measure of bleeding risk — the liver makes less of the anticoagulant proteins too — and reflexive correction of a number is a well-described error.

Practical use in the ED

1. Decide on the bleed, not the INR. Intracranial haemorrhage, major gastrointestinal bleeding, and bleeding into a critical space are what justify PCC. An INR of 8 with no bleeding is a vitamin K problem, not a concentrate problem.
2. Send an INR, but do not wait for it if the bleed is catastrophic — the >6 dose band is the default in that situation, and the level can be reconciled afterwards.
3. Prescribe the vitamin K in the same breath. The Konakion MM label gives 5 mg IV for major bleeding and 5–10 mg for life-threatening bleeding — not one range for both. Make it a single decision so it cannot be forgotten.
4. Ask about heparin-induced thrombocytopenia. It is a contraindication, and the alternative product will not be in your fridge.
5. Cap the weight at 100 kg and check the maximum single dose for the INR band.
6. Tell the receiving team when the PCC was given. Six to eight hours later is when the rebound happens, and the person managing it will not be you.

Critical appraisal

1. PCC's superiority over plasma is established for INR correction and much less so for outcomes. Randomised comparisons show faster and more complete correction of the INR with less volume, which is not in dispute. Demonstrating that this translates into fewer deaths or less disability after intracranial haemorrhage is far harder, and the mortality evidence is weaker than the enthusiasm.
2. Dosing by INR band is a convention, not a validated model. The bands come from the product labels and are described in the SmPC itself as empirical, with the acknowledgement that recovery and duration of effect vary. Fixed-dose regimens — typically 1000 or 1500 IU regardless of INR and weight — are used in several centres and have comparable observational results, faster administration and less waste. That is an unresolved and clinically live question, and departments differ.
3. Thrombotic risk is real but poorly quantified in this population. Patients receiving PCC are anticoagulated for a reason and are then given a procoagulant while bleeding. Reported thrombotic rates vary widely between series, and separating drug effect from the underlying risk is close to impossible without a control arm.
4. The vitamin K co-administration failure is a systems problem with a known fix. The rebound is entirely predictable, the remedy is a cheap ampoule, and the omission still happens — usually because the two are prescribed by different people at different moments. Linking them in the same order set removes most of it.

References

1. 1
   Octaplex 1000 IU powder and solvent for solution for injection — Summary of Product Characteristics, Octapharma Limited. electronic Medicines Compendium. Sections 2, 4.1–4.4, 4.8, 5.2. Source of the composition, INR dose table, 100 kg cap, infusion rate, contraindications and factor half-lives. Verified 23 Aug 2026.
2. 2
   Octaplex 500 IU powder and solvent for solution for injection — Summary of Product Characteristics, Octapharma Limited. electronic Medicines Compendium
3. 3
   Konakion MM 10 mg/ml solution for injection — Summary of Product Characteristics, section 4.2. electronic Medicines Compendium. Gives 5 mg IV vitamin K with PCC for major bleeding and 5–10 mg for life-threatening bleeding on warfarin.
4. 4
   Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin — fourth edition. British Committee for Standards in Haematology. Br J Haematol 2011;154(3):311–24. PubMed
5. 5
   Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013;128(11):1234–43. PubMed
6. 6
   NICE. Blood transfusion. NICE guideline NG24. nice.org.uk/guidance/ng24